Epidermal growth factor receptor 425 monoclonal antibodies radiolabeled with iodine-125 in the adjuvant treatment of high-grade astrocytomas

• Published in: Hybridoma Vol. 14; no. 2; p. 111
• Main Authors: Snelling, L, Miyamoto, C T, Bender, H, Brady, L W, Steplewski, Z, Class, R, Emrich, J, Rackover, M A
• Format: Journal Article
• Language: English
• Published: United States 01-04-1995
• Subjects: Adjuvants, Immunologic - therapeutic use; Adult; Aged; Antibodies, Monoclonal - therapeutic use; Astrocytoma - radiotherapy; Female; Glioblastoma - radiotherapy; Humans; Iodine Radioisotopes - therapeutic use; Male; Middle Aged; Radiotherapy, Adjuvant; Receptor, Epidermal Growth Factor - immunology; Supratentorial Neoplasms - radiotherapy
• ISSN: 0272-457X
• DOI: 10.1089/hyb.1995.14.111

Fifty-nine patients with primary presentation of high-grade gliomas of the brain, 13 with astrocytomas with anaplastic foci and 46 with glioblastoma multiforme, were treated with surgical intervention and definitive postoperative radiation therapy followed by multiple intravenous administration of iodine-125-labeled monoclonal antibody-425, which binds specifically to human epidermal growth factor receptor. The total cumulative labeled antibody doses ranged from 40 to 296 mCi. The administration of the radiolabeled antibody was performed in most instances within 3 months following completion of the primary surgery and radiation therapy. No significant life-threatening toxicities were observed during the trial. At one year, 34 (58%) of the 59 patients in the trial were alive. The median overall survival for both groups was 13.5 months.